Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rockwell Medical (RMTI) Capital Expenditures (2016 - 2025)

Rockwell Medical (RMTI) has disclosed Capital Expenditures for 16 consecutive years, with $229000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Capital Expenditures rose 19.9% year-over-year to $229000.0, compared with a TTM value of $851000.0 through Sep 2025, up 29.14%, and an annual FY2024 reading of $1.0 million, up 255.99% over the prior year.
  • Capital Expenditures was $229000.0 for Q3 2025 at Rockwell Medical, up from $164000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $395000.0 in Q4 2024 and bottomed at -$80000.0 in Q3 2022.
  • Average Capital Expenditures over 5 years is $134421.1, with a median of $127000.0 recorded in 2021.
  • The sharpest move saw Capital Expenditures crashed 162.99% in 2022, then skyrocketed 1093.75% in 2024.
  • Year by year, Capital Expenditures stood at $114000.0 in 2021, then skyrocketed by 146.49% to $281000.0 in 2022, then plummeted by 84.7% to $43000.0 in 2023, then surged by 818.6% to $395000.0 in 2024, then crashed by 42.03% to $229000.0 in 2025.
  • Business Quant data shows Capital Expenditures for RMTI at $229000.0 in Q3 2025, $164000.0 in Q2 2025, and $63000.0 in Q1 2025.